Advertisement

Recent advances in experimental polyphosphazene adjuvants and their mechanisms of action

  • Royford Magiri
  • George Mutwiri
  • Heather L. Wilson
Mini Review

Abstract

Vaccination continues to be a very important public health intervention to control infectious diseases in the world. Subunit vaccines are generally poorly immunogenic and require the addition of adjuvants to induce protective immune responses. Despite their critical role in vaccines, adjuvant mechanism of action remains poorly understood, which is a barrier to the development of new, safe and effective vaccines. In the present review, we focus on recent progress in understanding the mechanisms of action of the experimental adjuvants poly[di(carboxylatophenoxy)phosphazene] (PCPP) and poly[di(sodiumcarboxylatoethyl-phenoxy)phosphazene] (PCEP) (in this review, adjuvants PCPP and PCEP are collectively referred to as PZ denoting polyphosphazenes). PZs are high molecular weight, water-soluble, synthetic polymers that have been shown to regulate innate immune response genes, induce cytokines and chemokines secretion at the site of injection and, also, induce immune cell recruitment to the site of injection to create a local immune-competent environment. There is an evidence that as well as its role as an immunoadjuvant (that activate innate immune responses), PZ can also act as a vaccine carrier. The mechanism of action that explains how PZ leads to these effects is not known and is a barrier to the development of designer vaccines.

Keywords

Adjuvant Vaccine Mechanism of action Polyphosphazene Innate immunity 

Notes

Funding information

Financial support for this work was provided by the Saskatchewan Agriculture Development Fund (20150263). H.L.W. is an adjunct professor in the Department of Veterinary Microbiology and the School of Public Health at the University of Saskatchewan. G.K.M. is a professor in the School of Public Health, University of Saskatchewan and a Research Scientist at VIDO-InterVac. This manuscript was published with permission from the Director of VIDO-InterVac as journal series number 838.

References

  1. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lolekha S, Peltola H, Ruff T (2008) Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ 86(2):140–146CrossRefGoogle Scholar
  2. Andrianov AK, Payne LG (1998) Protein release from polyphosphazene matrices. Adv Drug Deliv Rev 31(3):185–196CrossRefGoogle Scholar
  3. Andrianov AK, Svirkin YY, LeGolvan MP (2004) Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomacromolecules 5(5):1999–2006CrossRefGoogle Scholar
  4. Andrianov AK, Marin A, Roberts BE (2005) Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 6(3):1375–1379CrossRefGoogle Scholar
  5. Andrianov AK, Marin A, Chen J (2006) Synthesis, properties, and biological activity of poly [di (sodium carboxylatoethylphenoxy) phosphazene]. Biomacromolecules 7(1):394–399CrossRefGoogle Scholar
  6. Andrianov AK, DeCollibus DP, Gillis HA, Henry HK, Marin A, Prausnitz MR, Babiuk LA, Townsend H, Mutwiri G (2009) Poly [di (carboxylatophenoxy) phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci U S A 106(45):18936–18941CrossRefGoogle Scholar
  7. Andrianov AK, Decollibus DP, Marin A, Webb A, Griffin Y, Webby RJ (2011) PCPP Babiuk, H. H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies. J Pharm Sci 100(4):1436–1443CrossRefGoogle Scholar
  8. Andrianov AK, Marin A, Fuerst TR (2016a) Molecular-level interactions of polyphosphazene immunoadjuvants and their potential role in antigen presentation and cell stimulation. Biomacromolecules 17(11):3732–3742CrossRefGoogle Scholar
  9. Andrianov AK, Marin A, Fuerst TR (2016b) Self-assembly of polyphosphazene immunoadjuvant with poly (ethylene oxide) enables advanced nanoscale delivery modalities and regulated pH-dependent cellular membrane activity. Heliyon 2(4):e00102CrossRefGoogle Scholar
  10. Apostólico J d S, Lunardelli VAS, Coirada FC, Boscardin SB, Rosa DS (2016) Adjuvants: classification, modus operandi, and licensing. J Immunol Res 2016Google Scholar
  11. Awate S, Wilson HL, Lai K, Babiuk LA, Mutwiri G (2012) Activation of adjuvant core response genes by the novel adjuvant PCEP. Mol Immunol 51(3–4):292–303CrossRefGoogle Scholar
  12. Awate S, Eng NF, Gerdts V, Babiuk LA, Mutwiri G (2014a) Caspase-1 dependent IL-1β secretion and antigen-specific T-cell activation by the novel adjuvant, PCEP. Vaccine 2(3):500–514CrossRefGoogle Scholar
  13. Awate S, Wilson HL, Singh B, Babiuk LA, Mutwiri G (2014b) The adjuvant PCEP induces recruitment of myeloid and lymphoid cells at the injection site and draining lymph node. Vaccine 32(21):2420–2427CrossRefGoogle Scholar
  14. Castellino F, Galli G, Del Giudice G, Rappuoli R (2009) Generating memory with vaccination. Eur J Immunol 39(8):2100–2105CrossRefGoogle Scholar
  15. Ciabattini A, Pettini E, Fiorino F, Pastore G, Andersen P, Pozzi G, Medaglini D (2016) Modulation of primary immune response by different vaccine adjuvants. Front Immunol 7:427CrossRefGoogle Scholar
  16. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33(4):492–503CrossRefGoogle Scholar
  17. Dar A, Lai K, Dent D, Potter A, Gerdts V, Babiuk LA, Mutwiri GK (2012) Administration of poly [di (sodium carboxylatoethylphenoxy)] phosphazene (PCEP) as adjuvant activated mixed Th1/Th2 immune responses in pigs. Vet Immunol Immunopathol 146(3):289–295CrossRefGoogle Scholar
  18. De Temmerman M-L, Rejman J, Demeester J, Irvine DJ, Gander B, De Smedt SC (2011) Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today 16(13–14):569–582CrossRefGoogle Scholar
  19. Didierlaurent AM, Laupèze B, Di Pasquale A, Hergli N, Collignon C, Garçon N (2017) Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Exp Rev Vaccines 16(1):55–63CrossRefGoogle Scholar
  20. Edelman R (1992) An update on vaccine adjuvants in clinical trial. AIDS Res Hum Retrovir 8(8):1409–1411CrossRefGoogle Scholar
  21. Eng NF, Garlapati S, Gerdts V, Babiuk LA, Mutwiri GK (2010) PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens. J Immune Based Ther Vaccines 8:4CrossRefGoogle Scholar
  22. Garlapati S, Eng NF, Wilson HL, Buchanan R, Mutwiri GK, Babiuk LA, Gerdts V (2010) PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice. Vaccine 28(52):8306–8314CrossRefGoogle Scholar
  23. Garlapati S, Eng NF, Kiros TG, Kindrachuk J, Mutwiri GK, Hancock RE, Halperin SA, Potter AA, Babiuk LA, Gerdts V (2011) Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine 29(38):6540–6548CrossRefGoogle Scholar
  24. Gilbert P, Chiu Y-L, Allen M, Lawrence D, Chapdu C, Israel H, Holman D, Keefer M, Wolff M, Frey S (2003) Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine 21(21):2933–2947CrossRefGoogle Scholar
  25. Gracia A, Polewicz M, Halperin SA, Hancock RE, Potter AA, Babiuk LA, Gerdts V (2011) Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine 29(8):1595–1604CrossRefGoogle Scholar
  26. Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5(7):505–517Google Scholar
  27. Haghparast A, Zakeri A, Ebrahimian M, Ramezani M (2016) Targeting pattern recognition receptors (PRRs) in nano-adjuvants: current perspectives. Curr Bionanotechnol 2(1):47–59CrossRefGoogle Scholar
  28. Kindrachuk J, Jenssen H, Elliott M, Townsend R, Nijnik A, Lee SF, Gerdts V, Babiuk LA, Halperin SA, Hancock RE (2009) A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 27(34):4662–4671CrossRefGoogle Scholar
  29. Kovacs-Nolan J, Latimer L, Landi A, Jenssen H, Hancock R, Babiuk L (2009a) The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody-and cell-mediated immune responses in mice. Vaccine 27(14):2055–2064CrossRefGoogle Scholar
  30. Kovacs-Nolan J, Mapletoft J, Latimer L, Babiuk L (2009b) CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle. Vaccine 27(14):2048–2054CrossRefGoogle Scholar
  31. Kovacs-Nolan J, Mapletoft J, Lawman Z, Babiuk L (2009c) Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice. J Gen Virol 90(8):1892–1905CrossRefGoogle Scholar
  32. Le Cam NB, Ronco J, Francon A, Blondeau C, Fanget B (1998) Adjuvants for influenza vaccine. Res Immunol 149(1):19–23CrossRefGoogle Scholar
  33. Levast B, Awate S, Babiuk L, Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S (2014) Vaccine potentiation by combination adjuvants. Vaccines 2(2):297–322CrossRefGoogle Scholar
  34. Liu Z, Zhou C, Qin Y, Wang Z, Wang L, Wei X, Zhou Y, Li Q, Zhou H, Wang W (2017) Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine. Cell Disc 3:17007CrossRefGoogle Scholar
  35. Madan-Lala R, Pradhan P, Roy K (2017) Combinatorial delivery of dual and triple TLR agonists via polymeric pathogen-like particles synergistically enhances innate and adaptive immune responses. Sci Rep 7(1):2530CrossRefGoogle Scholar
  36. Magiri R, Lai K, Chaffey A, Wilson H, Berry W, Szafron M, Mutwiri G (2016) Response of immune response genes to adjuvants poly [di (sodium carboxylatoethylphenoxy) phosphazene](PCEP), CpG oligodeoxynucleotide and Emulsigen at intradermal injection site in pigs. Vet Immunol Immunopathol 175:57–63CrossRefGoogle Scholar
  37. Magiri R, Lai K, Chaffey A, Zhou Y, Pyo H-M, Gerdts V, Wilson HL, Mutwiri G (2018) Intradermal immunization with inactivated swine influenza virus and adjuvant polydi (sodium carboxylatoethylphenoxy) phosphazene (PCEP) induced humoral and cell-mediated immunity and reduced lung viral titres in pigs. Vaccine 36(12):1606–1613CrossRefGoogle Scholar
  38. Mapletoft JW, Oumouna M, Kovacs-Nolan J, Latimer L, Mutwiri G, Babiuk LA (2008) Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol 89(1):250–260CrossRefGoogle Scholar
  39. Mapletoft JW, Latimer L, Babiuk LA (2010) Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies. Clin Vaccine Immunol 17(1):23–35CrossRefGoogle Scholar
  40. Marin A, DeCollibus DP, Andrianov AK (2010) Protein stabilization in aqueous solutions of polyphosphazene polyelectrolyte and non-ionic surfactants. Biomacromolecules 11(9):2268–2273CrossRefGoogle Scholar
  41. McNeal MM, Rae MN, Ward RL (1999) Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17(11–12):1573–1580CrossRefGoogle Scholar
  42. Mohan T, Verma P, Rao DN (2013) Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res 138(5):779PubMedPubMedCentralGoogle Scholar
  43. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O'Hagan D, Rappuoli R, De Gregorio E (2008) Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Aca Sci U S A 105(30):10501–10506CrossRefGoogle Scholar
  44. Mount A, Koernig S, Silva A, Drane D, Maraskovsky E, Morelli AB (2013) Combination of adjuvants: the future of vaccine design. Exp Revs Vacc 12(7):733–746CrossRefGoogle Scholar
  45. Mutwiri G, Babiuk LA (2009) Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides. Adv Drug Deliv Rev 61(3):226–232CrossRefGoogle Scholar
  46. Mutwiri G, Benjamin P, Soita H, Townsend H, Yost R, Roberts B, Andrianov AK, Babiuk LA (2007) Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25(7):1204–1213CrossRefGoogle Scholar
  47. Mutwiri G, Benjamin P, Soita H, Babiuk LA (2008) Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with hepatitis B virus surface antigen. Vaccine 26(22):2680–2688CrossRefGoogle Scholar
  48. Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S, Auray G, Eng N, Garlapati S, Babiuk LA, Potter A (2011) Combination adjuvants: the next generation of adjuvants? Expert Rev Vaccines 10(1):95–107CrossRefGoogle Scholar
  49. Olive C (2012) Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Rev Vaccines 11(2):237–256CrossRefGoogle Scholar
  50. Palmer CD, Ninković J, Prokopowicz ZM, Mancuso CJ, Marin A, Andrianov AK, Dowling DJ, Levy O (2014) The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cells. Biomaterials 35(31):8876–8886CrossRefGoogle Scholar
  51. Pashine A, Valiante NM, Ulmer JB (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11(4s):S63CrossRefGoogle Scholar
  52. Pasquale AD, Preiss S, Silva FTD, Garçon N (2015) Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccine 3(2):320–343CrossRefGoogle Scholar
  53. Pasternak JA, Hamonic G, Forsberg NM, Wheler CL, Dyck MK, Wilson HL (2017) Intrauterine delivery of subunit vaccines induces a systemic and mucosal immune response in rabbits. Am J Reprod Immunol. 78(5). doi:  https://doi.org/10.1111/aji.1273
  54. Pasternak JA, Hamonic G, Van Kessel J, Wheler CL, Dyck MK, Wilson HL (2018) Intrauterine vaccination induces a dose-sensitive primary humoral response with limited evidence of recall potential. Am J Reprod Immunol 80:e12855.  https://doi.org/10.1111/aji.12855 CrossRefPubMedGoogle Scholar
  55. Payne LG, Jenkins SA, Andrianov A, Roberts BE (1995) Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm Biotechnol 6:473–493Google Scholar
  56. Petrovsky N (2015) Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf 38(11):1059–1074CrossRefGoogle Scholar
  57. Rajput ZI, Hu S-h, Xiao C-w, Arijo AG (2007) Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B 8(3):153–161CrossRefGoogle Scholar
  58. Reed SG, Orr MT, Fox CB (2013) Key roles of adjuvants in modern vaccines. Nat Med 19(12):1597CrossRefGoogle Scholar
  59. Ryan EJ, Daly LM, Mills KH (2001) Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 19(8):293–304CrossRefGoogle Scholar
  60. Sadeghinia A, Nazarian S, Adeli Z (2015) Mechanisms and performances of adjuvants in vaccine immunogenicity. J Appl Biotechnol Rep 2(3):257–264Google Scholar
  61. Salvador A, Igartua M, Hernandez RM, Pedraz JL (2012) Combination of immune stimulating adjuvants with poly(lactide-co-glycolide) microspheres enhances the immune response of vaccines. Vaccine 30(3):589–596CrossRefGoogle Scholar
  62. Sarkander J, Hojyo S, Tokoyoda K (2016) Vaccination to gain humoral immune memory. Clin Transl Immunology 5(12):e120CrossRefGoogle Scholar
  63. Sasai M, Yamamoto M (2013) Pathogen recognition receptors: ligands and signaling pathways by Toll-like receptors. Internat Revs Immunol 32(2):116–133CrossRefGoogle Scholar
  64. Shim D-H, Ko H-J, Volker G, Potter AA, Mutwiri G, Babiuk LA, Kweon M-N (2010) Efficacy of poly [di (sodium carboxylatophenoxy) phosphazene](PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. Vaccine 28(11):2311–2317CrossRefGoogle Scholar
  65. Singh M, O’Hagan DT (2003) Recent advances in veterinary vaccine adjuvants. Int J Parasitol 33(5):469–478CrossRefGoogle Scholar
  66. Sivakumar S, Safhi MM, Kannadasan M, Sukumaran N (2011) Vaccine adjuvants–current status and prospects on controlled release adjuvancity. Saudi Pharmaceut J 19(4):197–206CrossRefGoogle Scholar
  67. Storni T, Kündig TM, Senti G, Johansen P (2005) Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rews 57(3):333–355CrossRefGoogle Scholar
  68. Teasdale I, Brüggemann O (2013) Polyphosphazenes: multifunctional, biodegradable vehicles for drug and gene delivery. Polymers 5(1):161–187CrossRefGoogle Scholar
  69. Ulmer JB, Valley U, Rappuoli R (2006) Vaccine manufacturing: challenges and solutions. Nat Biotechnol 24(11):1377CrossRefGoogle Scholar
  70. Weiner GJ, Liu H-M, Wooldridge JE, Dahle CE, Krieg AM (1997) Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 94(20):10833–10837CrossRefGoogle Scholar
  71. Wilson HL, Kovacs-Nolan J, Latimer L, Buchanan R, Gomis S, Babiuk L (2010) A novel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection. Vaccine 28(52):8288–8299CrossRefGoogle Scholar
  72. Wu TYH (2016) Strategies for designing synthetic immune agonists. Immunology 148(4):315–325CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Royford Magiri
    • 1
    • 2
  • George Mutwiri
    • 1
    • 2
  • Heather L. Wilson
    • 1
    • 2
    • 3
  1. 1.Vaccinology & Immunotherapeutics Program, School of Public HealthUniversity of SaskatchewanSaskatoonCanada
  2. 2.Vaccine & Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac)University of SaskatchewanSaskatoonCanada
  3. 3.VIDO-InterVacSaskatoonCanada

Personalised recommendations